Charles River Laboratories has named Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer. In this role, Dr. Bumpus will lead the Company?s scientific strategy, oversee research and development initiatives, and advance innovation to support clients in accelerating the drug development process. Last October prior to joining the Company, Charles River announced that Dr. Bumpus would lead its Scientific Advisory Board, which provides guidance to strengthen the Company?s commercial and regulatory strategy.
In addition, the Scientific Advisory Board is focused on developing and accelerating the adoption of NAMs across the biopharmaceutical industry. Prior to Charles River, Dr. Bumpus joined the Food and Drug Administration (FDA) in August 2022 as Chief Scientist and later served as the agency?s Principal Deputy Commissioner until December 2024. Before joining the FDA, Dr. Bumpus was Professor and Director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
